http://www.zacks.com/stock/news/657613/regeneron-reports-positive-data-on-rare-blood-disorder-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-657613
Dec 06, 2019 - Regeneron (REGN) announces positive top-line data from a phase II study on rare blood disorder drug.
zc:1883212510357856013
0
https://seekingalpha.com/article/4310267-regeneron-pharmaceuticals-inc-regn-management-presents-piper-jaffray-31st-annual-healthcare?source=feed_sector_healthcare
Dec 03, 2019 - Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Piper Jaffray 31st Annual Healthcare Conference Call December 3, 2019 08:00 a.m. ET Company Representatives Bob Landry - Chief Financial Officer Justin Ho
0
sa:2847218734590993488
0
http://www.zacks.com/stock/news/646584/alnylam-gets-second-product-approval-amid-stiff-competition?cid=CS-ZC-FT-analyst_blog|zer_report_update-646584
Nov 29, 2019 - Alnylam (ALNY) gets FDA approval for givosiran injection for subcutaneous use to treat adults with acute hepatic porphyria. Givosiran injection will be marketed by the trade name of Givlaari.
zc:-5104077936089519122
0
http://www.zacks.com/stock/news/645048/regn-or-bmrn-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-645048
Nov 28, 2019 - REGN vs. BMRN: Which Stock Is the Better Value Option?
zc:2570501659400869972
0
http://www.zacks.com/stock/news/627538/4-big-biotech-stocks-worth-considering-post-q3-earnings?cid=CS-ZC-FT-analyst_blog|investment_ideas-627538
Nov 19, 2019 - We highlight a few principal players from the biotech sector, which are likely to witness a winning run in the near term.
zc:1176994761799375095
0
http://www.zacks.com/stock/news/619720/glaxos-nucala-meets-goal-in-rare-inflammatory-disorder-study?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-619720
Nov 14, 2019 - GlaxoSmithKline's (GSK) late-stage study evaluating Nucala succeeds in reducing flares in patients with Hypereosinophilic Syndrome.
zc:4563665915683175477
0
http://www.zacks.com/stock/news/615903/regn-or-bmrn-which-is-the-better-value-stock-right-now?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-615903
Nov 12, 2019 - REGN vs. BMRN: Which Stock Is the Better Value Option?
zc:-5294042248399286807
0
http://www.zacks.com/stock/news/614198/celgene-celg-hits-52-week-high-can-the-run-continue?cid=CS-ZC-FT-52_week_high-614198
Nov 11, 2019 - Celgene (CELG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
zc:-7985857366987258571
0
http://www.zacks.com/research-daily/608378/top-stock-reports-for-alibaba-general-electric-anthem?cid=CS-ZC-FT-research_daily-608378
Nov 07, 2019 - Top Stock Reports for Alibaba, General Electric & Anthem
zc:-7071297949843352282
0
https://www.fool.com/earnings/call-transcripts/2019/11/05/regeneron-pharmaceuticals-regn-q3-2019-earnings-ca.aspx?source=iedfolrf0000001
Nov 05, 2019 - REGN earnings call for the period ending September 30, 2019.
0
fool:3407556710236739144
0